You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
GEMCITABINE SANDOZ is indicated for treatment of patients with:. - locally advanced or metastatic non-small cell lung cancer (NSCLC). - locally advanced or metastatic adenocarcinoma of the pancreas . - Fluorouracil refractory pancreatic cancer. - (alone or in combination with cisplatin) bladder cancer. - (in combination with paclitaxel) unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.. - (in combination with carboplatin) recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.
GEMCITABINE SANDOZ is indicated for treatment of patients with:. - locally advanced or metastatic non-small cell lung cancer (NSCLC). - locally advanced or metastatic adenocarcinoma of the pancreas . - Fluorouracil refractory pancreatic cancer. - (alone or in combination with cisplatin) bladder cancer. - (in combination with paclitaxel) unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.. - (in combination with carboplatin) recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.
GEMCITABINE SANDOZ is indicated for treatment of patients with:. - locally advanced or metastatic non-small cell lung cancer (NSCLC). - locally advanced or metastatic adenocarcinoma of the pancreas . - Fluorouracil refractory pancreatic cancer. - (alone or in combination with cisplatin) bladder cancer. - (in combination with paclitaxel) unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.. - (in combination with carboplatin) recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.
? Treatment of patients with locally advanced or metastatic non-small cell lung cancer.
? Treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.
? Treatment of patients with 5FU refractory pancreatic cancer.
? Treatment of patients with bladder cancer, alone or in combination with cisplatin.
? Treatment, in combination with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.
? Treatment, in combination with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed > six months following platinum based therapy.
Treatment of patients with locally advanced or metastatic non-small cell lung cancer.
? Treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.
? Treatment of patients with 5FU refractory pancreatic cancer.
? Treatment of patients with bladder cancer, alone or in combination with cisplatin.
? Treatment, in combination with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.
? Treatment, in combination with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed > six months following platinum based therapy.
Treatment of patients with locally advanced or metastatic non-small cell lung cancer.
? Treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.
? Treatment of patients with 5FU refractory pancreatic cancer.
? Treatment of patients with bladder cancer, alone or in combination with cisplatin.
? Treatment, in combination with paclitaxel, of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated.
? Treatment, in combination with carboplatin, of patients with recurrent epithelial ovarian carcinoma, who have relapsed > six months following platinum based therapy.
Gemcitabine Ebewe is indicated for treatment of patients with: . - locally advanced or metastatic non-small cell lung cancer (NSCLC) . - locally advanced or metastatic adenocarcinoma of the pancreas. - fluorouracil refractory pancreatic cancer. - (alone or in combination with cisplatin) bladder cancer. . - (in combination with paclitaxel) unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. . - (in combination with carboplatin) recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.
Gemcitabine Ebewe is indicated for treatment of patients with: . - locally advanced or metastatic non-small cell lung cancer (NSCLC) . - locally advanced or metastatic adenocarcinoma of the pancreas. - fluorouracil refractory pancreatic cancer. - (alone or in combination with cisplatin) bladder cancer. . - (in combination with paclitaxel) unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. . - (in combination with carboplatin) recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.
Gemcitabine Ebewe is indicated for treatment of patients with: . - locally advanced or metastatic non-small cell lung cancer (NSCLC) . - locally advanced or metastatic adenocarcinoma of the pancreas. - fluorouracil refractory pancreatic cancer. - (alone or in combination with cisplatin) bladder cancer. . - (in combination with paclitaxel) unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. . - (in combination with carboplatin) recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
